Occasional incidents of acute overdosage of nitrofurantoin have not resulted in any specific symptoms other than vomiting. Induction of emesis is recommended. There is no specific antidote, but a high fluid intake should be maintained to promote urinary excretion of the drug. Nitrofurantoin is dialyzable.
Nitrofurantoin Capsules, USP (monohydrate/macrocrystals) should be taken with food.
Adults and Pediatric Patients Over 12 Years: One 100 mg capsule every 12 hours for seven days.
Nitrofurantoin Capsules, USP (monohydrate/macrocrystals) is available as 100 mg opaque yellowish brown and pale yellow capsules imprinted “101” on both cap and body.
- NDC 68788-8258-0 bottle of 10
Storage and Handling
Store at 20° to 25°C (68° to 77°F) [See USP controlled room temperature.]
Controlled clinical trials comparing Nitrofurantoin Capsules, USP (monohydrate/macrocrystals) 100 mg p.o. q12h and nitrofurantoin (macrocrystals) capsule 50 mg p.o. q6h in the treatment of acute uncomplicated urinary tract infections demonstrated approximately 75% microbiologic eradication of susceptible pathogens in each treatment group.
Mfg. By: Swiss Pharmaceutical Co. Inc.
Tainan City, 74442 Taiwan
Mfg. for: Trigen Laboratories, LLC
Alpharetta, GA 30005
PLR-NITRO-00002 Rev.: 11/2021
Repackaged By: Preferred Pharmaceuticals Inc.
| NITROFURANTOIN |
|Labeler — Preferred Pharmaceuticals Inc. (791119022)|
|Registrant — Preferred Pharmaceuticals Inc. (791119022)|
|Preferred Pharmaceuticals Inc.||791119022||REPACK (68788-8258)|
Revised: 09/2022 Preferred Pharmaceuticals Inc.
RxDrugLabels.com provides trustworthy package insert and label information about marketed prescription drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by RxDrugLabels.com. Every individual prescription drug label and package insert entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.